Gordon B. Mills, MD, PhD, The University of Texas MD Anderson Cancer Center, discusses assay of the genome in order to further measure DNA and RNA.
Mills says there is an incredible amount of new information arising from the cancer genome atlas, as well as similar programs in the academic community. Thus far, information has mostly focused on the DNA and RNA levels so far. Mills and his colleagues are investigating a protein-based analysis of the cancer genome.
This provides new information and opportunities that were not previously present, says Mills.
Gordon B. Mills, MD, PhD, professor of medicine and immunology, Olga Keith Wiess Distinguished University Chair for Cancer Research, co-director, Zayed Institute for Personalized Cancer Therapy, chair, Department of Systems Biology, Ann Rife Cox Chair in Gynecology, administrative director, Kleberg Center for Molecular Markers, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses assay of the genome in order to further measure DNA and RNA.
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More